Evaluation of biocompatibility and anti-glioma effi cacy of doxorubicin and irinotecan drug-eluting bead suspensions in alginate

Clinical and Translational Oncology

Volumn 14, Issue 1, 2012, Pages 50-59

  Glage, Silke ^a   Lewis, Andrew L ^b   Mertens, Patricia ^c   Baltes, Steffen ^c   Geigle, Peter ^d   Brinker, Thomas ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b BIOCOMPATIBLES UK LTD   (United Kingdom)

^c INTERNATIONAL NEUROSCIENCE INSTITUTE   (Germany)

^d CellMed AG   (Germany)

Author keywords

Alginate; Doxorubicin; Drug eluting beads; High grade glioma; Irinotecan; Locoregional chemotherapy

Indexed keywords

ALGINIC ACID; DOXORUBICIN; DRUG ELUTING BEAD; IRINOTECAN; KI 67 ANTIGEN; MICROSPHERE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ELUTION; EXCIPIENT COMPATIBILITY; FEMALE; FLUORESCENCE MICROSCOPY; GLIOMA; HISTOCOMPATIBILITY; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LOADING DRUG DOSE; MALE; NONHUMAN; RAT; TUMOR VOLUME;

ALGINATES; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; GLIOMA; GLUCURONIC ACID; HEXURONIC ACIDS; MALE; MATERIALS TESTING; MICROSPHERES; RATS; SURVIVAL RATE; SUSPENSIONS; TUMOR BURDEN;

EID: 84860729233     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0761-y     Document Type: Article

References (35)

1. Stupp R, van den Bent MJ, Hegi ME (2005) Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep 5:198-206 (Pubitemid 40873035)
2. Stupp R, Mayer M, Kann R et al (2009) Neoadju-vant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol 10:785-793
3. Gururangan S, Friedman HS (2002) Innovations in design and delivery of chemotherapy for brain tumors. Neuroimaging Clin N Am 12:583-597 (Pubitemid 36015493)
4. Lesniak MS, Brem H (2004) Targeted therapy for brain tumours. Nat Rev Drug Discov 3:499-508 (Pubitemid 38807532)
5. Rautioa J, Chikhale PJ (2004) Drug delivery systems for brain tumor therapy. Curr Pharm Des 10:1341-1353 (Pubitemid 38559751)
6. Guerin C, Olivi A, Weingart JD et al (2004) Recent advances in brain tumor therapy: local in-tracerebral drug delivery by polymers. Invest New Drugs 22:27-37 (Pubitemid 38196980)
7. Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. NeuroOncol 5:79-88 (Pubitemid 36422560)
8. Hart MG, Grant R, Garside R et al (2008) Che-motherapeutic wafers for high grade glioma. Co-chrane Database Syst Rev CD007294
9. Ranganath SH, Kee I, Krantz WB et al (2009) Hydrogel matrix entrapping PLGA-paclitaxel microspheres: drug delivery with near zero-order release and implantability advantages for malignant brain tumour chemotherapy. Pharm Res 26:2101-2114
10. Emerich DF, Winn SR, Hu Y et al (2000) Injectable chemotherapeutic microspheres and glioma I: enhanced survival following implantation into the cavity wall of debulked tumors. Pharm Res 17:767-775 (Pubitemid 30666955)
11. Li KW, Dang W, Tyler BM et al (2003) Polilacto-fate microspheres for paclitaxel delivery to central nervous system malignancies. Clin Cancer Res 9: 3441-3447 (Pubitemid 37082742)
12. Storm PB, Renard VM, Moriarity JL et al (2004) Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma. Cancer Chemother Pharmacol 54:361-367 (Pubitemid 39304431)
13. Menei P, Jadaud E, Faisant N et al (2004) Stereo-taxic implantation of 5-fluorouracil-releasing mi-crospheres in malignant glioma. Cancer 100:405-410 (Pubitemid 38063652)
14. Menei P, Capelle L, Guyotat J et al (2005) Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of malignant glioma: a randomized phase II trial. Neurosurgery 56:242-248
15. Lesniak MS, Upadhyay U, Goodwin R et al (2005) Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res 25:3825-3831 (Pubitemid 41665151)
16. Wang PP, Frazier J, Brem H (2002) Local drug delivery to the brain. Adv Drug Deliv Rev 54:987-1013
17. Kunwar S, Chang S, Westphal M et al (2010) Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glio-blastoma. Neuro Oncol 12:871-881
18. Lewis AL, Gonzalez MV, Lloyd AW et al (2006) DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 17:335-342 (Pubitemid 44341453)
19. Gonzalez M V, Tang Y, Phillips GJ et al (2008) Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro:in-vivo correlation. J Mater Sci Mater Med 19:767-775 (Pubitemid 351244006)
20. Baltes S, Freund I, Lewis AL et al (2010) Doxoru-bicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model. J Mater Sci Mater Med 21:1393-1402
21. Taylor RR, Tang Y, Gonzalez MV et al (2007) Iri-notecan drug eluting beads for use in chemoem-bolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 30:7-14 (Pubitemid 44908921)
22. Druckrey H, Landschutz C, Ivankovic S (1970) [Transplacental induction of malignant tumours of the nervous system. II. Ethyl-nitrosurea in 10 genetically defined strains of rats] Transplacentare Erzeugung maligner Tumoren des Nervensystems. II. Athyl-nitrosoharnstoff an 10 genetisch definierten Rattenstammen. Z Krebsforsch 73:371-386
23. Brownlee IA, Allen A, Pearson JP et al (2005) Al-ginate as a source of dietary fiber. Crit Rev Food Sci Nutr 45:497-510
24. Tonnesen HH, Karlsen J (2002) Alginate in drug delivery systems. Drug Dev Ind Pharm 28:621-630 (Pubitemid 34809561)
25. Jork A, Thürmer F, Cramer H et al (2000) Biocompatible alginate from freshly collected Lami-naria pallida for implantation. Appl Microbiol Biotechnol 53: 224-229 (Pubitemid 30120576)
26. Elstad NL, Fowers KD (2009) OncoGel (ReGel/paclitaxel): clinical applications for a novel pa-clitaxel delivery system. Adv Drug Deliv Rev 61:785-794
27. Tyler B, Fowers KD, Li KW et al (2010) A thermal gel depot for local delivery of paclitaxel to treat experimental brain tumors in rats. J Neuro-surg 113:210-217
28. Neuwelt EA, Glasberg M, Frenkel E, Barnett P (1983) Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: neuro-pathological studies. Ann Neurol 14:316-324 (Pubitemid 13051235)
29. Zhou R, Mazurchuk R, Straubinger RM (2002) Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res 62:2561-2566 (Pubitemid 34462735)
30. Kikuchi T, Saito R, Sugiyama S et al (2008) Convection-enhanced delivery of polyethylene glycol-coated liposomal doxorubicin: characterization and efficacy in rat intracranial glioma models. J Neurosurg 109:867-873
31. von Eckardstein KL, Reszka R, Kiwit JC (2005) Intracavitary chemotherapy (paclitaxel/carbopla-tin liquid crystalline cubic phases) for recurrent glioblastoma: clinical observations. J Neurooncol 74:305-309 (Pubitemid 41444499)
32. Eyol E, Boleij A, Taylor RR et al (2008) Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin. Clin Exp Metastasis 25:273-282
33. Storm PB, Moriarity JL, Tyler B et al (2002) Polymer delivery of camptothecin against 9L gliosarcoma: release, distribution, and efficacy. J Neurooncol 56:209-217 (Pubitemid 34476989)
34. Abbott NJ (2004) Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology. Neurochem Int 45:545-552 (Pubitemid 38739482)
35. Kalyanasundaram S, Calhoun VD, Leong KW (1997) A finite element model for predicting the distribution of drugs delivered intracranially to the brain. Am J Physiol 273:R1810-1821 (Pubitemid 27518136)